NasdaqHealth CareHealth Care ServicesS&P SmallCap 600
$16.84
+0.35 (+2.12%)
Close of Nov 06, 2026 · end-of-day data
NEO 8-K filings in 2025
Every material Form 8-K NeoGenomics Laboratories filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
NeoGenomics said director Alison L. Hannah, MD, resigned effective December 31, 2025, and the Board appointed John P. "Jack" Kenny to fill the vacancy effective January 1, 2026. Kenny will serve until the 2026 annual meeting and will receive independent director compensation under the company's existing program. The change affects board composition but the filing does not report any financial figures.
Dr. Alison L. Hannah's resignation as director is effective December 31, 2025; the Board accepted it on December 23, 2025.
Jack Kenny was appointed to the Board effective January 1, 2026, to fill the vacancy.
Kenny previously served as President, Chief Executive Officer and Board Director of Meridian Bioscience, per the press release (Exhibit 99.1, dated December 29, 2025).
Kenny will serve until the 2026 annual meeting, and the filing reports no related-party transactions requiring disclosure under Item 404(a).
NeoGenomics reported third-quarter 2025 revenue up 12% year over year to $188 million, driven by 18% growth in clinical revenue. The net loss widened 53% to $27 million, and adjusted EBITDA fell 9% to $12.2 million, so revenue growth did not carry through to profit. The company re-affirmed its full-year 2025 guidance for revenue, net loss and adjusted EBITDA, which had been revised on July 29, 2025.
Q3 2025 consolidated revenue of $188 million, up 12%; clinical revenue up 18%, or 15% excluding the Pathline acquisition
Net loss of $27 million, up 53% from $18 million in Q3 2024; diluted loss of $0.21 per share
Q3 impairment charges of $7.1 million related to the planned sale of Trapelo; adjusted EBITDA of $12.2 million, down 9%
Full-year 2025 guidance re-affirmed: consolidated revenue $720 million to $726 million; net loss $116 million to $108 million; adjusted EBITDA $41 million to $44 million
NeoGenomics director Elizabeth Floegel gave notice on August 5, 2025 that she is resigning from the Board of Directors, effective immediately. The company said her decision did not stem from any disagreement with it on operations, policies or practices.
Director Elizabeth Floegel resigned from the Board of Directors, effective immediately
Resignation notice was provided to the company on August 5, 2025
Company states no disagreement on operations, policies or practices led to the resignation
Filing dated August 8, 2025, signed by EVP, General Counsel and Corporate Secretary Alicia C. Olivo
NeoGenomics reported second-quarter 2025 revenue of $181 million, up 10% from a year earlier, but its net loss widened to $45 million, including $20 million of impairment charges. The company also lowered its full-year 2025 revenue guidance to $720 million to $726 million from $747 million to $759 million, and widened its expected net loss, which matters to shareholders because it signals weaker results than previously expected.
Q2 2025 revenue rose 10% to $181 million; clinical revenue grew 16%, or 13% excluding Pathline
Q2 net loss increased 142% to $45 million, including $20 million of impairment charges; Adjusted EBITDA was $10.7 million, flat year over year
2025 revenue guidance lowered to $720 million-$726 million from $747 million-$759 million
2025 GAAP net loss guidance widened to $(116) million-$(108) million from $(85) million-$(77) million
NeoGenomics expanded its board from nine to ten members on June 19, 2025, and appointed Marjorie C. Green to fill the new seat. Green is currently Senior Vice President and Head of Oncology, Global Clinical Development at Merck. The filing reports no financial results or changes to guidance, so the appointment is the only shareholder-relevant event disclosed.
Board size increased from nine to ten members; Green appointed June 19, 2025
Green is currently Senior Vice President and Head of Oncology, Global Clinical Development at Merck
Previously held roles at Seagen and Genentech, per the press release
Will serve until the 2026 annual meeting of stockholders or earlier resignation or removal
At its May 22, 2025 annual meeting, NeoGenomics stockholders approved an amendment adding 4,325,000 shares to the 2023 Equity Incentive Plan, along with a one-year minimum vesting period and limits on share recycling. Stockholders also re-elected nine directors, approved executive pay on an advisory basis, and ratified Deloitte & Touche LLP as auditor.
Stockholders approved adding 4,325,000 shares to the 2023 Equity Incentive Plan, with 94.90% of votes cast in favor.
Amendment sets a one-year minimum vesting period for awards and prohibits re-use of shares withheld for taxes and net share counting on option exercises.
Board will hold advisory votes on named executive compensation every year, after 103,435,850 votes favored annual frequency.
Deloitte & Touche LLP was ratified as independent registered public accountant with 112,929,861 votes for (99.86% of votes cast).
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every NeoGenomics Laboratories filing is on SEC EDGAR ↗. 8-K briefs of other companies →